Summary:
- Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
- A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
- MACD is crossing MACD signal line at 0.8. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
(Bloomberg Opinion) -- Covid-19 vaccines, now closer to becoming widely available than ever, are the ultimate tool to help tame the virus and allow people to return to some semblance of pre-pandemic life. Despite the recent good news on their progress, though, it’s unclear whether they can truly deliver on the promise of a return to normal. Why? Because as much as some vaccines have proved effective in protecting against Covid-19 symptoms, they haven’t yet shown that they can stop the virus from...
Pfizer Inc. addresses safety concerns and virus efficacy amongst the elderly. Is it enough for the FDA to approve and for manufacturing to commence?
An end to the pandemic could be in sight with two vaccine programs recently presenting promising results from late stage studies. Successful interim data from both Pfizer/BioNTech and Moderna’s Covid-19 vaccine candidates means a vaccine could become available before the year’s end.It would be stating the obvious to say this is good news for all, but it does leave question marks regarding one particular group: namely the other companies in the Covid-19 vaccine race, such as Novavax (NVAX), for e...
Yahoo Finance’s Alexis Christoforous and Robert Litan, non-resident senior fellow at the Brookings Institution, discuss his proposal to pay Americans $1.000 to take the coronavirus vaccine.
The 94.5% effectiveness shown in the trial’s first interim glimpse has also led Wall Street to a mix of price target increases and rating downgrades. Moderna’s results looked even better than the “more than 90%” effectiveness reported a week earlier for a vaccine from (PFE) (PFE) and (BNTX) (BNTX). Wall Street’s average price target for Moderna stock is now $107, according to FactSet, compared with $92 a month ago.
As the coronavirus vaccine race continues, investors are increasingly ditching less prominent drugmakers exhibiting slow progress and/or financial woes; Inovio Pharmaceuticals (NASDAQ: INO) and Sorrento Therapeutics (NASDAQ: SRNE) are down between 8% and 36%, respectively, over the past month. In favor instead are large-cap sector players including Moderna (NASDAQ: MRNA) and AstraZeneca (NASDAQ: AZN), up 8% and 17%, respectively, in the same time frame. One small-cap biotech that's been surpri...
Yahoo Finance's Alexis Christoforous and Jared Holz, Jefferies Equity Desk Strategist, Healthcare, discuss vaccine outlook amid optimism from Moderna.
The biotech says the first glimpse of its clinical trial results showed its shots cut the rate of infections by 94.5%. Pfizer described its vaccine as more than 90% effective.
Yahoo Finance's Alexis Christoforous and Octavio Marenzi, Opimas CEO discuss market reaction to new coronavirus vaccine data from Moderna.
Investors are worried that Moderna's good news could be bad news for these coronavirus vaccine leaders.